EA201690557A1 - Способы лечения синдрома ломкой х-хромосомы и связанных расстройств - Google Patents

Способы лечения синдрома ломкой х-хромосомы и связанных расстройств

Info

Publication number
EA201690557A1
EA201690557A1 EA201690557A EA201690557A EA201690557A1 EA 201690557 A1 EA201690557 A1 EA 201690557A1 EA 201690557 A EA201690557 A EA 201690557A EA 201690557 A EA201690557 A EA 201690557A EA 201690557 A1 EA201690557 A1 EA 201690557A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
chromosome
brackle
related disorders
treating syndrome
Prior art date
Application number
EA201690557A
Other languages
English (en)
Inventor
Ярон Дэниели
Далия Мегиддо
Original Assignee
Алкобра Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Алкобра Лтд. filed Critical Алкобра Лтд.
Publication of EA201690557A1 publication Critical patent/EA201690557A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Данное изобретение относится к способам ослабления признака или симптома синдрома ломкой Х-хромосомы и связанных с ним расстройств, таких как расстройства аутистического спектра.
EA201690557A 2013-09-09 2014-09-09 Способы лечения синдрома ломкой х-хромосомы и связанных расстройств EA201690557A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
PCT/IB2014/002398 WO2015033224A2 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Publications (1)

Publication Number Publication Date
EA201690557A1 true EA201690557A1 (ru) 2016-07-29

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690557A EA201690557A1 (ru) 2013-09-09 2014-09-09 Способы лечения синдрома ломкой х-хромосомы и связанных расстройств
EA201690559A EA201690559A1 (ru) 2013-09-09 2014-09-09 Способы определения ответа на терапию

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201690559A EA201690559A1 (ru) 2013-09-09 2014-09-09 Способы определения ответа на терапию

Country Status (12)

Country Link
EP (2) EP3043792A2 (ru)
JP (2) JP2016530291A (ru)
KR (2) KR20160086818A (ru)
CN (2) CN105917225A (ru)
AU (2) AU2014315026A1 (ru)
CA (2) CA2922901A1 (ru)
EA (2) EA201690557A1 (ru)
IL (2) IL244343A0 (ru)
MX (2) MX2016003002A (ru)
SG (2) SG11201601830PA (ru)
TW (2) TW201605443A (ru)
WO (2) WO2015035402A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3027629B1 (en) * 2013-07-31 2017-06-14 UDC Ireland Limited Luminescent diazabenzimidazole carbene metal complexes
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
WO2019197632A1 (en) * 2018-04-13 2019-10-17 Healx Limited Treatment of fragile x syndrome
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
PL3813816T3 (pl) * 2018-06-07 2023-07-31 Ovid Therapeutics Inc. Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x
WO2021141426A1 (ko) * 2020-01-08 2021-07-15 건국대학교 글로컬산학협력단 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
US20230055339A1 (en) * 2020-02-07 2023-02-23 Neuroventi Composition comprising rilmenidine compound as active ingredient for treatment of fragile x syndrome or related developmental disability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
MX2011013775A (es) * 2009-06-25 2012-04-20 Alcobra Ltd Un metodo para el tratamiento, alivio de sitomas de, mitigacion, mejoramieto y prevencion de una enfermedad, desorden o condicion cognoscitiva.

Also Published As

Publication number Publication date
CA2923421A1 (en) 2015-03-12
MX2016003006A (es) 2016-06-10
EA201690559A1 (ru) 2016-08-31
WO2015035402A1 (en) 2015-03-12
IL244453A0 (en) 2016-04-21
AU2014315026A1 (en) 2016-03-24
JP2016530291A (ja) 2016-09-29
KR20160078956A (ko) 2016-07-05
EP3044589A1 (en) 2016-07-20
SG11201601830PA (en) 2016-04-28
WO2015033224A2 (en) 2015-03-12
JP2016530536A (ja) 2016-09-29
WO2015033224A3 (en) 2015-07-02
CN105517546A (zh) 2016-04-20
SG11201601605YA (en) 2016-04-28
TW201606304A (zh) 2016-02-16
AU2014316779A1 (en) 2016-03-17
KR20160086818A (ko) 2016-07-20
TW201605443A (zh) 2016-02-16
MX2016003002A (es) 2016-09-08
EP3043792A2 (en) 2016-07-20
CA2922901A1 (en) 2015-03-12
CN105917225A (zh) 2016-08-31
IL244343A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
EA201690557A1 (ru) Способы лечения синдрома ломкой х-хромосомы и связанных расстройств
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
CU20150094A7 (es) Imidazopiridazinas sustituídas
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MY176049A (en) Serine/threonine kinase inhibitors
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы